Response to Comments: Off-label Use of Rituximab and Rituximab Biosimilars

This response document (Policy A58727) concerns off-label use of rituximab and rituximab biosimilars for non-anti-neoplastic (non-oncologic) conditions and summarizes comments received during the public comment period. The excerpt provided does not include specific clinical coverage criteria, limitations, documentation requirements, or frequency limits; review of the full policy (DL38920) is required to extract actionable coverage rules.

"This policy addresses off-label use of rituximab and rituximab biosimilars for non-anti-neoplastic (non-oncologic) conditions and applies to such uses."

Sign up to see full coverage criteria, indications, and limitations.